You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.


In 2003 we reported on the outcomes of 88 patients with node positive disease who underwent radical prostatectomy and pelvic lymph node dissection (median 21 nodes) between 1989 and 1999. Patients with limited nodal disease appeared to have a good chance of long-term survival, even without immediate adjuvant therapy (androgen deprivation therapy and/or radiotherapy). In this study we update the followup in these patients and verify the reported projected probability of survival.

Materials and Methods:

The projected 10-year cancer specific survival probability after the initially reported followup of 3.2 years was 60% for these patients with node positive disease. The outcome has been updated after a median followup of 15.6 years.


Of the 39 patients with 1 positive node 7 (18%) remained biochemically relapse-free, 11 (28%) showed biochemical relapse only and 21 (54%) experienced clinical progression. Of these 39 patients 22 (57%) never required deferred androgen deprivation therapy and 12 (31%) died of prostate cancer. All patients with 2 (20) or more than 2 (29) positive nodes experienced biochemical relapse and only 5 (10%) of these 49 experienced no clinical progression. Of these 49 patients 39 (80%) received deferred androgen deprivation therapy.


Biochemical relapse is likely in patients with limited nodal disease after radical prostatectomy and pelvic lymph node dissection, but for 46% of patients this does not imply death from prostate cancer. Patients with 1 positive node have a good (75%) 10-year cancer specific survival probability and a 20% chance of remaining biochemical relapse-free even without immediate adjuvant therapy.


  • 1 : Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer. Eur J Cancer2013; 49: 616. Google Scholar
  • 2 : The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol1995; 153: 993. LinkGoogle Scholar
  • 3 : Pelvic lymph node dissection in prostate cancer. Eur Urol2009; 55: 1251. Google Scholar
  • 4 : Detection rate and operating time required for gamma probe-guided sentinel lymph node resection after injection of technetium-99m nanocolloid into the prostate with and without preoperative imaging. Eur Urol2007; 52: 126. Google Scholar
  • 5 : Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol2001; 166: 1715. LinkGoogle Scholar
  • 6 : The incidence and extent of pelvic lymph node metastases in apparently localized prostatic cancer. Cancer1981; 47: 2941. Google Scholar
  • 7 : Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate. Significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome. Urology1989; 33: 27. Google Scholar
  • 8 : Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. J Urol2012; 188: 73. LinkGoogle Scholar
  • 9 : Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am2001; 28: 555. Google Scholar
  • 10 : Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol2006; 176: 564. LinkGoogle Scholar
  • 11 : Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol2009; 55: 1003. Google Scholar
  • 12 : Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol2007; 178: 864. LinkGoogle Scholar
  • 13 : Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol2009; 55: 261. Google Scholar
  • 14 : Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med1999; 341: 1781. Crossref, MedlineGoogle Scholar
  • 15 : Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. J Urol2004; 171: 1128. LinkGoogle Scholar
  • 16 : Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?. J Urol2003; 169: 849. LinkGoogle Scholar
  • 17 : TNM Classification of Malignant Tumours, 6th Edition. New York: Wiley-Liss2002. Google Scholar
  • 18 : Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol2004; 172: 1840. LinkGoogle Scholar
  • 19 : Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol2002; 167: 1681. LinkGoogle Scholar
  • 20 : Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol2008; 54: 344. Google Scholar
  • 21 : Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer. J Urol2013; 189: 1314. LinkGoogle Scholar
  • 22 : Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol1990; 144: 1425. LinkGoogle Scholar
  • 23 : Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases. Prostate2009; 69: 352. Google Scholar
  • 24 : TNM Classification of Malignant Tumours, 7th Edition. New York: Wiley-Blackwell2009. Google Scholar
  • 25 : The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol2008; 53: 118. Google Scholar
  • 26 : Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am1997; 24: 395. Crossref, MedlineGoogle Scholar
  • 27 : Medicare reimbursement and prescribing hormone therapy for prostate cancer. J Natl Cancer Inst2010; 102: 1814. Google Scholar
  • 28 : Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol2008; 53: 941. Google Scholar